Sail Biomedicines Secures Grants for RNA Medicines Against Malaria

-Sail Biomedicines, Inc. (“Sail” or the “Company”), a Flagship Pioneering company and leader in RNA-based programmable medicines, a...

January 04, 2024 | Thursday | News
Junshi Biosciences Gets Approval for Toripalimab as Perioperative Treatment in Resectable NSCLC

Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company ded...

January 03, 2024 | Wednesday | News
Avenue Therapeutics Completes Enrollment in Clinical Trial for AJ201 in Kennedy's Disease

Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development...

January 03, 2024 | Wednesday | News
NKGen Biotech Initiates Phase 1/2a Trial for Alzheimer’s with SNK01 NK Cell Product

SNK01 consists of a non-genetically modified NK cell product with enhanced cytotoxicity and activating receptor expression for the treatment of moderate AD...

January 01, 2024 | Monday | News
Elpiscience, Astellas Partner on Bispecific Macrophage Engager

The two companies will collaboratively conduct early-stage research for these two programs. Elpiscience will also grant Astellas the right to add up to two...

December 28, 2023 | Thursday | News
Carrum Health Partners with Florida Cancer Specialists on Breast Cancer Treatment Model

Florida Cancer Specialists & Research Institute, LLC (FCS) announced today a new partnership with Carrum Health, a value-based Centers of Excellen...

December 26, 2023 | Tuesday | News
APhA and CDC Partner to Advance Health Equity and Prevent Heart Disease, Stroke

APhA's vision to inspire, innovate, and create opportunities for its members and pharmacists worldwide to optimize medication use and health for all is ali...

December 22, 2023 | Friday | News
Positive CHMP Opinion by EMA for Arpraziquantel to Treat Schistosomiasis in Preschool-Aged Children

EMA assessed arpraziquantel under the EU-M4all procedure for high-priority medicines intended for use in countries outside the European Union Merck is c...

December 20, 2023 | Wednesday | News
Compass Pathways reports positive tolerability results for investigational COMP360 psilocybin treatment in Phase 2 study for post-traumatic stress disorder

Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation ...

December 20, 2023 | Wednesday | News
Teva and Biolojic Design Ink Exclusive License for Atopic Dermatitis and Asthma Antibody Therapy

Biolojic’s BD9 is a multibody that was computationally designed as a multi specific antibody targeting IL-13 / TSLP to treat inflammatory diseases....

December 15, 2023 | Friday | News
Microbot Medical and Corewell Health Collaborate on LIBERTY® Robotic Surgical System for Telerobotic Procedures

Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System,announced it has entered into a collabo...

December 15, 2023 | Friday | News
LEQEMBI® to be launched in Japan for Alzheimer's disease on December 20

LEQEMBI obtained manufacturing and marketing approval for the indication of slowing progression of mild cognitive impairment (MCI) and mild dementia due to...

December 13, 2023 | Wednesday | News
AstraZeneca to Acquire Icosavax, Including Promising Phase II RSV and hMPV Combination Vaccine

AstraZeneca has entered into a definitive agreement to acquire Icosavax, Inc. (NASDAQ: ICVX), a US-based clinical-stage biopharmaceutical company focused o...

December 12, 2023 | Tuesday | News
Freya Biosciences Raises $38M in Significant Series A for Women’s Reproductive Immunotherapies

Series A led by Sofinnova Partners and OMX Ventures Freya Biosciences, a trans-Atlantic biotech company specializing in women's health, announced today a ...

December 12, 2023 | Tuesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close